Clinical Studies – Targeting Acute and Chronic Thromboembolic Disorders
____________
First Published, Prospective, International, Observational Study of a NOAC for the Treatment and Secondary Prevention of VTE
XALIA:
First Published, Prospective, International, Observational Study with a NOAC (Xarelto®) in DVT
Objective
Collect Real-World data in patients with acute DVT treated with Xarelto or standard anticoagulation therapy*
Study Design
- A large, multicentre, prospective, non-interventional study to evaluate the safety and efficacy of Xarelto in the Real World
- Patients were enrolled from June 2012 to March 2014 from 19 countries in Europe, plus Canada and Israel
Population
5,142 adults with acute DVT and an indication to receive anticoagulation therapy for at least 3 months, who were treated with Xarelto or standard anticoagulation therapy*
Key patient characteristics of Xarelto patients are consistent with EINSTEIN DVT


CrCl, creatinine clearance; DVT, deep vein thrombosis; VTE, venous thromboembolism. * Initial treatment with unfractionated heparin, low-molecular-weight heparin or fondaparinux; usually overlapping with and followed by a vitamin K antagonist.
PP-XAR-ALL-1819-1







